New study monitors infection risks in advanced myeloma drug
NCT ID NCT07564128
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Italian registry will follow 50 adults with relapsed/refractory multiple myeloma who are receiving elranatamab as part of their standard care. The goal is to track how many infections occur during the first year of treatment. The study does not test a new drug but aims to gather real-world data on infection patterns to improve patient management.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- elranatamab
- What this could lead to
- If successful, this study could help doctors better manage infection risks in patients receiving elranatamab for multiple myeloma.
- What could go wrong
- This is an observational registry, not a controlled trial, so it cannot prove elranatamab's effectiveness or safety. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MIELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat myeloma
- Can engineered immune cells outsmart Treatment-Resistant myeloma?
- Can a lower dose of a myeloma drug keep the disease in check with fewer side effects?
- A pre-treatment pill may supercharge cancer-fighting immune cells
- New antibody combo aims to stall multiple Myeloma's return
- Real-World data may reveal best Second-Line therapy for multiple myeloma